Beta-2 chimaerin (CHN2) (CHN2)

Beta-2 chimaerin, encoded by the CHN2 gene, is a Rac-specific GTPase-activating protein (GAP) that serves as a critical regulator of cellular signaling by promoting the inactivation of the small GTPase Rac1 (UniProt: P52757). It possesses a characteristic C1 regulatory domain—often referred to as the C1b domain due to its homology with Protein Kinase C—that binds to diacylglycerol (DAG) and phorbol esters, facilitating its translocation to the plasma membrane and subsequent activation of its GAP activity (Colon-Gonzalez & Kazanietz, 2006). Unlike the Protein Kinase C family, Beta-2 chimaerin functions independently of calcium, providing a distinct pathway for DAG-mediated signal transduction. Biologically, it is essential for modulating the actin cytoskeleton, which influences processes such as neurite outgrowth, T-cell receptor signaling, and cell migration (Silari et al., 2005). In clinical contexts, Beta-2 chimaerin is frequently identified as a tumor suppressor; its expression is often downregulated in aggressive forms of breast and prostate cancer, leading to hyperactivation of Rac1 and increased metastatic potential (Yang et al., 2005). Pharmacological targeting of the C1 domain with small molecules like bryostatins or synthetic DAG mimetics offers a strategy to modulate Rac1 activity for therapeutic benefit in oncology and neurology (Wang et al., 2006).

Other names

Beta-chimaerinRho GTPase-activating protein 3ARHGAP3BCHBeta-2 chimaerin C1b regulatory domain

Ligand binding to the C1 domain induces a conformational change and membrane translocation, which activates the C-terminal GAP domain to catalyze the hydrolysis of GTP bound to Rac1, thereby converting it to its inactive GDP-bound state (Colon-Gonzalez & Kazanietz, 2006).